Cite
MLA Citation
H. Hurwitz et al.. “2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC).” European journal of cancer, vol. 51, n.d., pp. S379–S380. http://access.bl.uk/ark:/81055/vdc_100030628213.0x00002e